From: Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer
Variable | PFS (OR, 95% CI) | OS (OR, 95% CI) | ||
---|---|---|---|---|
MDACC | JICR | MDACC | JICR | |
FIGO stage | ||||
 I | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
 II | 1.11 (0.44–2.81) | 1.27 (0.63–3.95) | 1.31 (0.45–3.77) | 1.62 (0.65–3.99) |
 III | 2.66 (1.25–5.66) | 4.19 (1.97–9.64) | 3.65 (1.56–9.17) | 4.79 (2.26–10.14) |
 IV | 3.03 (1.37–6.70) | 6.57 (3.05–13.69) | 5.38 (2.20–13.20) | 7.03 (3.28–15.05) |
Ascites | ||||
 No | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
 Yes | 1.73 (1.22–2.47) | 1.93 (1.52–2.42) | 1.92 (1.42–2.60) | 2.04 (1.61–2.58) |
Residual tumors | ||||
 No | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
 Yes | 1.54 (1.10–2.14) | 1.68 (1.15–2.40) | 1.99 (1.63–2.63) | 2.10 (1.67–2.56) |
Neo-chemotherapy | ||||
 Yes | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
 No | 1.38 (1.01–1.95) | 1.45 (1.14–1.78) | 1.33 (0.40–3.56) | 1.12 (0.84–1.60) |
Chemotherapy, including paclitaxel | ||||
 Yes | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
 No | 1.01 (0.82–1.47) | 1.12 (1.00–1.44) | 1.30 (0.41–4.10) | 1.18 (0.80–1.63) |
CA-125, decreasing kinetics | ||||
 ≥1/32 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
 <1/32 | 1.12 (1.06–1.47) | 1.50 (1.23–1.85) | 1.17 (0.62–2.27) | 1.09 (0.67–2.21) |
Baseline CA-125 | 1.02 (1.01–1.06) | 1.03 (1.01–1.06) | 1.03 (1.01–1.05) | 1.06 (1.02–1.10) |
CA-125 level at relapse | 1.01 (1.00–1.01) | 1.01 (1.00–1.02) | 1.01 (1.00–1.01) | 1.01 (1.00–1.13) |
Nadir CA-125 | 1.04 (1.02–1.08) | 1.06 (1.02–1.09) | 1.02 (1.01–1.04) | 1.04 (1.01–1.07) |